Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS
Go back to Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 196.58 -2.09 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $198.67 | 52 Week High | $333.65 | |||
| Open | $200.22 | 52 Week Low | $223.02 | |||
| Day High | $200.99 | P/E | 25.17 | |||
| Day Low | $193.20 | EPS | $7.81 | |||
| Volume | 1,729,827 | |||||
